Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Bunkyo-ku
Clinical trial register · Japan

Clinical Trials in Bunkyo-ku, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Sapporo 33 Nagoya 30 Yokohama 27 Fukuoka 19 Suita 19
Narrow the registerReset
Recruitment status
Phase
Site location
Sapporo33 Nagoya30 Yokohama27 Fukuoka19 Suita19
All 135 locations
Target enrolment
to

Trials with a site in Bunkyo-ku

22 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Nagoya, Gifu, Bunkyo Ku, Kodaira, Yonago
2026-06-03
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Kamogawa, Sapporo, Kobe, Shiwa-Gun, Tsu, Bunkyo Ku, Bunkyo-ku, Chūō
2026-05-27
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Sagamihara, Kashihara, Bunkyo Ku
2026-03-24
Recruiting
Novartis Pharmaceuticals
Observational
30
Kurume, Osaka, Suita, Bunkyo Ku
2026-03-23
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Kobe, Bunkyo Ku, Chiyoda-ku
2026-03-09
Active, closed
Novartis Pharmaceuticals
Phase 1
6
Nagoya, Kobe, Bunkyo Ku, Koto Ku
2025-11-26
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Chikushino-shi, Kitakyushu, Kamakura, Sagamihara, Bunkyo Ku
2025-10-03
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Chiba, Sapporo, Kobe, Sendai, Suita, Bunkyo Ku, Shinjuku-ku, Fukuoka
2025-03-13
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals
Phase 2
21
Sapporo, Yokohama, Sendai, Suita, Izumo, Bunkyo-ku, Shinjuku-ku, Fukuoka
2024-12-17
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Sapporo, Sendai, Suita, Bunkyo-ku, Fukuoka, Ishikawa, Kyoto
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Nagoya, Toyoake, Yokohama, Iruma-gun, Bunkyo-ku, Shinjuku Ku, Toyama, Hiroshima
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Chiba, Sapporo, Kobe, Yokohama, Sendai, Suita, Izumo, Bunkyo Ku
2024-09-04
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo-ku, Chuo Ku, Fuchū, Itabashi-ku
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Matsumoto-shi, Iruma-gun, Bunkyo Ku
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Kitakyushu, Sapporo, Kamimashi-gun, Habikino, Takatsuki, Ōtsu, Izumo, Bunkyo-ku
2023-12-07
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Nagoya, Kitakyushu, Sapporo, Yokohama, Kuwana, Sasebo, Kurashiki, Bunkyo Ku
2023-10-27
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo Ku, Bunkyo-ku, Chuo Ku, Fuchū
2023-03-02
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Nagoya, Kitakyushu, Sapporo, Yokohama, Kuwana, Sasebo, Kurashiki, Bunkyo Ku
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Osaka, Bunkyo Ku, Koto Ku
2022-07-07
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Nagoya, Sapporo, Kobe, Yokohama, Kumamoto, Suita, Kitaadachi-gun, Bunkyo Ku
2021-06-09
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals
Phase 1/2
217
Sapporo, Bunkyo Ku, Fukuoka
2019-06-26
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
Novartis Pharmaceuticals
Phase 4
279
Nagoya, Sapporo, Isehara, Suita, Bunkyo Ku, Fukuoka, Osaka
2015-03-05
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/bunkyo-ku

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies with a site in Bunkyo-ku that also match the filters currently applied.

How many clinical trials are recruiting in Bunkyo-ku?

8 of the 22 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bunkyo-ku), 22 studies
PhaseStudiesRecruitingShare
Phase 311650%
Phase 26127.3%
Phase 4209.1%
Observational114.5%
Phase 1104.5%
Phase 1/2104.5%

Most active sponsors

Lead sponsors with the most studies (Bunkyo-ku)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals228
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.